Baheen Qais, Wu Xin, Liu Wanlin, Xie Jiangping, Zhang Bo, Ma Zhiqiang
Department of Gastrointestinal Tumor Center, Beijing Arion Cancer, Beijing 102600, P.R. China.
Department of Pathology, Beijing Arion Cancer, Beijing 102600, P.R. China.
Mol Clin Oncol. 2025 Aug 14;23(5):94. doi: 10.3892/mco.2025.2889. eCollection 2025 Nov.
Retroperitoneal leiomyosarcomas (RPLMS) are rare invasive malignant tumors originating from the smooth muscle of the retroperitoneum. Although metastasis mainly involves the lungs, liver and vascular regions, cutaneous metastasis is extremely rare, occurring in 1-2.6% of reported cases. This type of metastasis usually indicates disease progression, poor prognosis, median progression free survival of ~5 months, and overall survival of 14-17 months. Although recent molecular analyses have improved our understanding of the pathophysiology of leiomyosarcoma (LMS), the treatment of advanced LMS remains challenging, and there are few series of articles published primarily in case form. The present review explores the epidemiology, pathophysiology, clinical manifestations, diagnostic methods, and treatment strategies of skin metastasis in advanced RPLMS, in order to provide further reference.
腹膜后平滑肌肉瘤(RPLMS)是起源于腹膜后平滑肌的罕见侵袭性恶性肿瘤。虽然转移主要累及肺、肝和血管区域,但皮肤转移极为罕见,在报告病例中发生率为1%-2.6%。这种转移类型通常表明疾病进展、预后不良、无进展生存期中位数约为5个月,总生存期为14-17个月。尽管最近的分子分析增进了我们对平滑肌肉瘤(LMS)病理生理学的理解,但晚期LMS的治疗仍然具有挑战性,且很少有以病例形式为主发表的系列文章。本综述探讨晚期RPLMS皮肤转移的流行病学、病理生理学、临床表现、诊断方法和治疗策略,以便提供进一步参考。